<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30227299</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-1967</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>70</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer treatment reviews</Title>                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>            </Journal>            <ArticleTitle>Tumor-associated macrophages in breast cancer: Innocent bystander or important player?</ArticleTitle>            <Pagination>                <MedlinePgn>178-189</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(18)30146-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2018.08.010</ELocationID>            <Abstract>                <AbstractText>Tumor-associated macrophages (TAMs) are important tumor-promoting cells in the breast tumor microenvironment. Preclinically TAMs stimulate breast tumor progression, including tumor cell growth, invasion and metastasis. TAMs also induce resistance to multiple types of treatment in breast cancer models. The underlying mechanisms include: induction and maintenance of tumor-promoting phenotype in TAMs, inhibition of CD8+ T cell function, degradation of extracellular matrix, stimulation of angiogenesis and inhibition of phagocytosis. Several studies reported that high TAM infiltration of breast tumors is correlated with a worse patient prognosis. Based on these findings, macrophage-targeted treatment strategies have been developed and are currently being evaluated in clinical breast cancer trials. These strategies include: inhibition of macrophage recruitment, repolarization of TAMs to an antitumor phenotype, and enhancement of macrophage-mediated tumor cell killing or phagocytosis. This review summarizes the functional aspects of TAMs and the rationale and current evidence for TAMs as a therapeutic target in breast cancer.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Qiu</LastName>                    <ForeName>Si-Qi</ForeName>                    <Initials>SQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; The Breast Center, Cancer Hospital of Shantou University Medical College, Raoping 7, 515041 Shantou, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Waaijer</LastName>                    <ForeName>Stijn J H</ForeName>                    <Initials>SJH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zwager</LastName>                    <ForeName>Mieke C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>de Vries</LastName>                    <ForeName>Elisabeth G E</ForeName>                    <Initials>EGE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>van der Vegt</LastName>                    <ForeName>Bert</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schröder</LastName>                    <ForeName>Carolien P</ForeName>                    <Initials>CP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. Electronic address: c.p.schroder@umcg.nl.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Cancer Treat Rev</MedlineTA>            <NlmUniqueID>7502030</NlmUniqueID>            <ISSNLinking>0305-7372</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Macrophage</Keyword>            <Keyword MajorTopicYN="N">Targeted therapy</Keyword>            <Keyword MajorTopicYN="N">Treatment resistance</Keyword>            <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30227299</ArticleId>            <ArticleId IdType="pii">S0305-7372(18)30146-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.ctrv.2018.08.010</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>